Want to see KR:003000 full AI Analyst Report?
Bukwang Pharmaceutical Co., Ltd. (003000) Income Statement
Bukwang Pharmaceutical Co., Ltd. Income Statement
Last quarter (Q2 2026), Bukwang Pharmaceutical Co., Ltd.'s total revenue was $56.99B, an increase of 33.84% from the same quarter last year. In Q2, Bukwang Pharmaceutical Co., Ltd.'s net income was $1.40B. See Bukwang Pharmaceutical Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 200.71B | $ 160.09B | $ 125.93B | $ 190.91B | $ 182.49B | |
| $ 95.72B | $ 74.34B | $ 50.05B | $ 79.43B | $ 75.76B | |
| $ 81.56B | $ 72.73B | $ 87.54B | $ 79.66B | $ 70.14B | |
| Depreciation and Amortization | $ 5.49B | $ 4.11B | $ 4.29B | $ 5.12B | $ 4.84B |
| $ 19.65B | $ 7.63B | $ -31.47B | $ 4.89B | $ 11.40B | |
| $ 14.16B | $ 1.62B | $ -37.50B | $ -230.64M | $ 5.62B | |
| $ -7.78B | $ -4.59B | $ -2.07B | $ -802.24M | $ -1.83B | |
| $ 6.39B | $ -2.97B | $ -39.57B | $ -1.03B | $ 3.79B | |
| $ 12.57B | $ -2.64B | $ -31.33B | $ -2.47B | $ -916.62M | |
| Per Share Metrics | |||||
| Basic EPS | $ 152.00 | $ -38.59 | $ -458.00 | $ -36.15 | $ -13.39 |
| Diluted EPS | $ 152.00 | $ -38.59 | $ -457.67 | $ -36.15 | $ -13.39 |
| Weighted Average Shares Outstanding | 98.67M | 68.45M | 68.41M | 68.45M | 68.46M |
| Weighted Average Shares Outstanding (Diluted) | 98.67M | 68.45M | 68.45M | 68.45M | 68.46M |
Currency in KRW
